Table 2 Cost, effect, and incremental cost-effectiveness ratio of symptom management, pirfenidone, and nintedanib for patients with idiopathic pulmonary fibrosis
|  | Cost ($) | Δ Cost | Effect (QALYs) | Δ Effect | ICER |
|---|---|---|---|---|---|
Symptom management | $ 79,815 | Â | 3.78 | Â | Â |
Nintedanib | $ 675,544 | $ 595,729 | 4.15 | 0.37 | $ 1,601,224 |
Pirfenidone | $ 688,778 | $ 13,233 | 4.10 | − 0.05 | DOMINATED |